Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials.

Publication Type:

Journal Article


Archives of internal medicine, Volume 170, Issue 18, p.1678-85 (2010)


2010, Aged, Center-Authored Paper, Clinical Trials as Topic, Confidence Intervals, Drug Combinations, Drug Therapy, Combination, Estrogen Replacement Therapy, Estrogens, Estrogens, Conjugated (USP), Female, Humans, Hysterectomy, Incidence, Medroxyprogesterone Acetate, Middle Aged, Nephrolithiasis, Odds Ratio, Postmenopause, Public Health Sciences Division, Risk Assessment, Risk Factors, United States


Observational studies examining the role of estrogen in the risk of kidney stone formation have shown conflicting results. However, randomized trial evidence on nephrolithiasis risk with estrogen therapy in postmenopausal women is lacking.